vTv Therapeutics (NASDAQ:VTVT) and Strongbridge Biopharma (NASDAQ:SBBP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, analyst recommendations and profitability.
This table compares vTv Therapeutics and Strongbridge Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
5.6% of vTv Therapeutics shares are held by institutional investors. Comparatively, 50.1% of Strongbridge Biopharma shares are held by institutional investors. 1.7% of vTv Therapeutics shares are held by insiders. Comparatively, 5.1% of Strongbridge Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of recent ratings for vTv Therapeutics and Strongbridge Biopharma, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
vTv Therapeutics currently has a consensus price target of $6.50, indicating a potential upside of 333.33%. Strongbridge Biopharma has a consensus price target of $12.80, indicating a potential upside of 591.89%. Given Strongbridge Biopharma’s higher probable upside, analysts plainly believe Strongbridge Biopharma is more favorable than vTv Therapeutics.
Valuation and Earnings
This table compares vTv Therapeutics and Strongbridge Biopharma’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|vTv Therapeutics||$12.43 million||6.53||-$7.91 million||($0.69)||-2.17|
|Strongbridge Biopharma||$18.03 million||5.56||$31.85 million||$0.31||5.97|
Strongbridge Biopharma has higher revenue and earnings than vTv Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Strongbridge Biopharma, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
vTv Therapeutics has a beta of -3.58, suggesting that its share price is 458% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500.
Strongbridge Biopharma beats vTv Therapeutics on 12 of the 13 factors compared between the two stocks.
vTv Therapeutics Company Profile
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops orally administered small molecule drug candidates to fill unmet medical needs. The company is developing Azeliragon, an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase II/III clinical trials for the treatment of mild Alzheimer's disease. It is also developing TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase IIb clinical trials to treat type 2 diabetes, as well as is in Phase II clinical trials for treating type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. In addition, the company is developing a portfolio of investigational drug candidates, such as HPP737 and HPP971 to treat inflammatory disorders. It has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593. vTv Therapeutics Inc. also has license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; Novo Nordisk A/S; and Columbia University. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing's syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.